Ramucirumab resistance management

Ramucirumab is a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2). It is used to treat a variety of solid tumors, such as gastric cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, etc. Sometimes patients may develop drug resistance after receiving ramucirumab treatment, but everyone has a different constitution and has different drug resistance responses. If you feel unwell, please inform your doctor in time.

Doctors may consider combining ramucirumab with other treatment modalities, such as chemotherapy drugs, targeted therapy drugs, or immunotherapy, which can overcome resistance by increasing the combined effect of treatment. Patients should be monitored for tumor markers, such as changes in tumor marker concentration in the blood. If elevated tumor markers or other abnormalities are found, treatment may need to be adjusted. Try using it in combination with other therapeutics targeting different signaling pathways to increase the anti-tumor effect.

Ramosizumab is usually an injection preparation. The original drug has been on the market in China, but it has been on the market for a short time and has not been included in the medical insurance. The price of 100mg/10mL per box may be around RMB 5,000, and the price of 500mg/50mL per box may be around RMB 17,000. The price of the original Hong Kong version of 100mg/10mL may be around RMB 8,400 per box, and the price of 500mg/50mL per box may be around RMB 28,000 (the price may fluctuate due to exchange rates), and their pharmaceutical ingredients are basically the same. Currently, there are no generic drugs produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.